Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Glenmark’s Seretide stymied in Germany

Executive Summary

Glenmark’s planned launch of its generic of GlaxoSmithKline’s (GSK’s) Seretide Accuhaler (fluticasone/salmeterol) dry-powder inhaler in Germany has been thwarted by an injunction, a setback that the Indian firm insists will not have a “material impact” on either its European or group operations. “In the last two to three days, GSK was able to get a preliminary injunction in Germany,” chairman and managing director Glenn Saldanha told investors during Glenmark’s second quarter earnings conference call, “which we are trying to vacate as we speak.” It was a trademark issue, he revealed, noting that the injunction did not pertain to a patent.

You may also be interested in...



Seretide Settlement Lifts Glenmark In Europe

Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.

Glenmark Plans To Spin Out A US-Based ‘Innovation’ Business – And May Pull The Plug On Advair

Having amassed a significant pipeline of innovative assets, India’s Glenmark has made the choice to spin them off into a new company that will be housed in the US. 

What’s Next? Five Things To Look Out For In October

A busy October will include planned biosimilar launches and key appointments for the off-patent sector.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB001477

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel